Novel biomarkers for cardiovascular risk prediction

Journal of Geriatric Cardiology

Volumn 14, Issue 2, 2017, Pages 135-150

  Wang, Juan ^a   Tan, Guo Juan ^a   Han, Li Na ^a   Bai, Yong Yi ^a   He, Miao ^b   Liu, Hong Bin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINA NATIONAL PETROLEUM CORPORATION   (China)

Author keywords

Biomarker; Cardiovascular disease; Prediction; Risk stratification

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; COPEPTIN; ENDOTHELIN 1; FATTY ACID BINDING PROTEIN; FIBRINOGEN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; MATRIX METALLOPROTEINASE; MICRORNA; MID REGIONAL PRO ADRENOMEDULLIN; MYELOPEROXIDASE; NATRIURETIC FACTOR; NEU DIFFERENTIATION FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROADRENOMEDULLIN; SECRETORY PHOSPHOLIPASE A2; TROPONIN; UNCLASSIFIED DRUG; URIC ACID;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HORMONAL REGULATION; HUMAN; MYOCARDIAL STRESS; NEUROHORMONAL ACTIVATION; PLAQUE INSTABILITY; PLAQUE RUPTURE; PREDICTION; REVIEW; STRESS; THROMBOCYTE ACTIVATION;

EID: 85021050676     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.11909/j.issn.1671-5411.2017.02.008     Document Type: Review

References (167)

1. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015; 386: 2287-2323.
2. Hozawa A, Folsom AR, Sharrett AR, et al. Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects-atherosclerosis risk in communities study. Arch Intern Med 2007; 167: 573-579.
3. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
4. Redberg RF, Vogel RA, Criqui MH, et al. 34th Bethesda conference: task force #3-what is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol 2003; 41: 1886-1898.
5. Hoff J, Wehner W, Nambi V. Troponin in cardiovascular disease prevention: updates and future direction. Curr Atheroscler Rep 2016; 18: 12.
6. Safford MM, Parmar G, Barasch CS, et al. Hospital laboratory reporting may be a barrier to detection of 'microsize' myocardial infarction in the US: an observational study. BMC Health Serv Res 2013; 13: 162.
7. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567.
8. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol 2013; 61: 1753-1758.
9. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315.
10. Cullen L, Mueller C, Parsonage WA, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol 2013; 62: 1242-1249.
11. Haaf P, Drexler B, Reichlin T, et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation 2012; 126: 31-40.
12. Everett BM, Brooks MM, Vlachos HE, et al. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015; 373: 610-620.
13. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352: 15-35.
14. McMahon CG, Lamont JV, Curtin E, et al. Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. TAm J Emerg Med 2012; 30: 267-274.
15. Gami BN, Patel DS, Haridas N, et al. Utility of heart-type fatty acid binding protein as a new biochemical marker for the early diagnosis of acute coronary syndrome. J Clin Diagn Res 2015; 9: Bc22-Bc24.
16. Kabekkodu SP, Mananje SR, Saya RP. A study on the role of heart type fatty acid binding protein in the diagnosis of acute myocardial infarction. J Clin Diagn Res 2016; 10: Oc07- Oc10.
17. Otaki Y, Watanabe T, Takahashi H, et al. Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study. PLoS One 2014; 9: e94834.
18. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439-493.
19. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
20. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
21. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
22. Jaber BL, Madias NE. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 1603-1605.
23. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-140.
24. Oemrawsingh RM, Cheng JM, Akkerhuis KM, et al. High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention 2016; 12: 345-351.
25. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology working group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015; 241: 507-532.
26. Lane T, Wassef N, Poole S, et al. Infusion of pharmaceutical- grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res 2014; 114: 672-676.
27. Noveck R, Stroes ES, Flaim JD, et al. Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers. J Am Heart Assoc 2014; 3.
28. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302: 37-48.
29. Wiklund FE, Bennet AM, Magnusson PK, et al. Macrophage inhibitory cytokine-1 (mic-1/gdf15): a new marker of all-cause mortality. Aging Cell 2010; 9: 1057-1064.
30. Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (aristotle) trial. Circulation 2014; 130: 1847-1858.
31. Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 2012; 9: 337-345.
32. Kempf T, Zarbock A, Widera C, et al. Gdf-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011; 17: 581-588.
33. Daniels LB, Clopton P, Laughlin GA, et al. Growth-differentiation factor-15 is a robust, independent predictor of 11- year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 2011; 123: 2101-2110.
34. Eggers KM, Kempf T, Larsson A, et al. Evaluation of temporal changes in cardiovascular biomarker concentrations improves risk prediction in an elderly population from the community. Clin Chem 2016; 62: 485-493.
35. Cotter G, Voors AA, Prescott MF, et al. Growth differentiation factor 15 (gdf-15) in patients admitted for acute heart failure: results from the relax-ahf study. Eur J Heart Fail 2015; 17: 1133-1143.
36. Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 2007; 116: 1540-1548.
37. Ho JE, Mahajan A, Chen MH, et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 2012; 58: 1582-1591.
38. Minamisawa M, Motoki H, Izawa A, et al. Comparison of inflammatory biomarkers in outpatients with prior myocardial infarction. Int Heart J 2016; 57: 11-17.
39. Hagstrom E, James SK, Bertilsson M, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J 2016; 37: 1325-1333.
40. Fuernau G, Poenisch C, Eitel I, et al. Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Iabp-shock II-trial. Eur J Heart Fail 2014; 16: 880-887.
41. Damman P, Kempf T, Windhausen F, et al. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Int J Cardiol 2014; 172: 356-363.
42. Widera C, Pencina MJ, Bobadilla M, et al. Incremental prognostic value of biomarkers beyond the Grace (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin t in non-ST-elevation acute coronary syndrome. Clin Chem 2013; 59: 1497-1505.
43. Schnabel RB, Yin X, Larson MG, et al. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol 2013; 33: 1728-1733.
44. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007; 115: 962-971.
45. Lowe GD. Fibrinogen assays for cardiovascular risk assessment. Clin Chem 2010; 56: 693-695.
46. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA 47 Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310-1320.
47. Appiah D, Schreiner PJ, MacLehose RF, et al. Association of plasma gamma' fibrinogen with incident cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 2015; 35: 2700-2706.
48. Becatti M, Marcucci R, Bruschi G, et al. Oxidative modification of fibrinogen is associated with altered function and structure in the subacute phase of myocardial infarction. Arterioscler Thromb Vasc Biol 2014; 34: 1355-1361.
49. Fabbrini E, Serafini M, Colic Baric I, et al. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes 2014; 63: 976-981.
50. Jin YL, Zhu T, Xu L, et al. Uric acid levels, even in the normal range, are associated with increased cardiovascular risk: the Guangzhou Biobank Cohort Study. Int J Cardiol 2013; 168: 2238-2241.
51. Dutta A, Henley W, Pilling LC, et al. Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc 2013; 61: 319-326.
52. Zhao G, Huang L, Song M, et al. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 2013; 231: 61-68.
53. Fenech G, Rajzbaum G, Mazighi M, et al. Serum uric acid and cardiovascular risk: state of the art and perspectives. Joint Bone Spine 2014; 81: 392-397.
54. Jee SH, Lee SY, Kim MT. Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil 2004; 11: 185-191.
55. You L, Liu A, Wuyun G, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian Area. J Atheroscler Thromb 2014; 21: 355-365 57 Kleber ME, Delgado G, Grammer TB, et al. Uric acid and cardiovascular events: a mendelian randomization study. J Am Soc Nephrol 2015; 26: 2831-2838.
56. Resl M, Clodi M, Neuhold S, et al. Serum uric acid is related to cardiovascular events and correlates with n-terminal pro-b- type natriuretic peptide and albuminuria in patients with diabetes mellitus. Diabet Med 2012; 29: 721-725.
57. Wang JG, Staessen JA, Fagard RH, et al. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37: 1069-1074.
58. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a Preventive Cardiology Information System (PRECIS) database cohort study. Arthritis Rheum 2008; 58: 623-630.
59. Wald NJ, George L, Smith D, et al. Serum screening for down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. BJOG 1996; 103: 407-412.
60. Sangiorgi G, Mauriello A, Bonanno E, et al. Pregnancyassociated plasma protein-A is markedly expressed by monocyte- macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol 2006; 47: 2201-2211.
61. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy- associated plasma protein a as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022-1029.
62. Lund J, Qin QP, Ilva T, et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003; 108: 1924-1926.
63. Heeschen C, Dimmeler S, Hamm CW, et al. Pregnancyassociated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol 2005; 45: 229-237.
64. Lund J, Qin QP, Ilva T, et al. Pregnancy-associated plasma protein a: a biomarker in acute ST-elevation myocardial infarction (stemi). Ann Med 2006; 38: 221-228.
65. Bonaca MP, Scirica BM, Sabatine MS, et al. Prospective evaluation of pregnancy-associated plasma protein-A and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol 2012; 60: 332-338.
66. Wu XF, Yang M, Qu AJ, et al. Level of pregnancy-associated plasma protein-A correlates with coronary thin-cap fibroatheroma burden in patients with coronary artery disease: novel findings from 3-vessel virtual histology intravascular ultrasound assessment. Medicine 2016; 95: e2563.
67. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1102-1111.
68. Yunoki K, Naruko T, Inaba M, et al. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease. Atherosclerosis 2013; 231: 308-314.
69. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-2142.
70. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the epic-norfolk prospective population study. J Am Coll Cardiol 2007; 50: 159-165.
71. Sawicki M, Sypniewska G, Kozinski M, et al. Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. Eur J Clin Invest 2011; 41: 667-671.
72. Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007; 49: 2364-2370.
73. Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007; 99: 1364-1368.
74. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445.
75. Nicholls SJ, Tang WH, Brennan D, et al. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem 2011; 57: 1762-1770.
76. Newby AC. Metalloproteinases promote plaque rupture and myocardial infarction: a persuasive concept waiting for clinical translation. Matrix Biol 2015; 44-46: 157-166.
77. Gu W, Liu W, Yang X, et al. Cutis laxa: analysis of metalloproteinases and extracellular matrix expression by immunohistochemistry and histochemistry. Eur J Dermatol 2011; 21: 717-721.
78. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004; 110: 337-343.
79. Kunte H, Amberger N, Busch MA, et al. Markers of insta bility in high-risk carotid plaques are reduced by statins. J Vasc Surg 2008; 47: 513-522.
80. Wang LX, Lu SZ, Zhang WJ, et al. Comparision of high sensitivity C-reactive protein and matrix metalloproteinase 9 in patients with unstable angina between with and without significant coronary artery plaques. Chin Med J (Engl) 2011; 124: 1657-1661.
81. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008; 29: 2116-2124.
82. Kelly D, Cockerill G, Ng LL, et al. Plasma matrix metalloproteinase- 9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007; 28: 711-718.
83. Dhillon OS, Khan SQ, Narayan HK, et al. Matrix metalloproteinase- 2 predicts mortality in patients with acute coronary syndrome. Clin Sci (Lond) 2010; 118: 249-257.
84. Lenti M, Falcinelli E, Pompili M, et al. Matrix metalloproteinase- 2 of human carotid atherosclerotic plaques promotes platelet activation. Correlation with ischaemic events. Thromb Haemost 2014; 111: 1089-1101.
85. Peeters W, Moll FL, Vink A, et al. Collagenase matrix metalloproteinase- 8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J 2011; 32: 2314-2325.
86. Goncalves I, Bengtsson E, Colhoun HM, et al. Elevated plasma levels of mmp-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes. Arterioscler Thromb Vasc Biol 2015; 35: 1723-1731.
87. Burke JE, Dennis EA. Phospholipase a2 biochemistry. Cardiovasc Drugs Ther 2009; 23: 49-59.
88. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein- associated phospholipase a2 as an independent predictor of coronary heart disease. West of Scotland coronary prevention study group. N Engl J Med 2000; 343: 1148-1155.
89. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
90. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370: 1702-1711.
91. Mullard A. Gsk's darapladib failures dim hopes for anti-inflammatory heart drugs. Nat Rev Drug Discov 2014; 13: 481-482.
92. Stafforini DM, McIntyre TM, Zimmerman GA, et al. Platelet- activating factor acetylhydrolases. J Biol Chem 1997; 272: 17895-17898.
93. Jonsson-Rylander AC, Lundin S, Rosengren B, et al. Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep 2008; 10: 252-259.
94. Menschikowski M, Kasper M, Lattke P, et al. Secretory group ii phospholipase a2 in human atherosclerotic plaques. Atherosclerosis 1995; 118: 173-181.
95. Rosengren B, Peilot H, Umaerus M, et al. Secretory phospholipase a2 group v: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a western diet. Arterioscler Thromb Vasc Biol 2006; 26: 1579-1585.
96. Leitinger N, Watson AD, Hama SY, et al. Role of group ii secretory phospholipase a2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 1999; 19: 1291-1298.
97. Henderson WR, Jr., Chi EY, Bollinger JG, et al. Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med 2007; 204: 865-877.
98. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase a2 activity and risk of incident coronary events in healthy men and women: the epic-norfolk study. Arterioscler Thromb Vasc Biol 2007; 27: 1177-1183.
99. Lind L, Simon T, Johansson L, et al. Circulating levels of secretory- and lipoprotein-associated phospholipase a2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J 2012; 33: 2946-2954.
100. Ryu SK, Mallat Z, Benessiano J, et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation 2012; 125: 757-766.
101. Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014; 311: 252-262.
102. Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet 2015; 47: 856-860.
103. Anand SX, Viles-Gonzalez JF, Badimon JJ, et al. Membrane- associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-384.
104. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
105. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-2268.
106. Li J, Wang Y, Lin J, et al. Soluble cd40l is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke 2015; 46: 1990-1992.
107. Plaikner M, Peer A, Falkensammer G, et al. Lack of association of soluble CD40 ligand with the presence of acute myocardial infarction or ischemic stroke in the emergency department. Clin Chem 2009; 55: 175-178.
108. Liebetrau C, Hoffmann J, Dorr O, et al. Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction. Circ Res 2015; 116: 867-875.
109. Bolignano D, Cabassi A, Fiaccadori E, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med 2014; 52: 1447-1456.
110. Katan M, Morgenthaler N, Widmer I, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008; 29: 341-346.
111. Sorensen NA, Shah AS, Ojeda FM, et al. High-sensitivity troponin and novel biomarkers for the early diagnosis of non-ST-segment elevation myocardial infarction in patients with atrial fibrillation. Eur Heart J Acute Cardiovasc Care. 2016; 5: 419-427.
112. Greisenegger S, Segal HC, Burgess AI, et al. Copeptin and long-term risk of recurrent vascular events after transient ischemic attack and ischemic stroke: population-based study. Stroke 2015; 46: 3117-3123.
113. Lee JH, Chan YH, Lai OF, et al. Vasopressin and copeptin levels in children with sepsis and septic shock. Intensive Care Med 2013; 39: 747-753.
114. Alcoba G, Manzano S, Lacroix L, et al. Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study. BMC Infect Dis 2015; 15: 347.
115. Tasevska I, Enhorning S, Persson M, et al. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart 2016; 102: 127-132.
116. Boeckel JN, Oppermann J, Anadol R, et al. Analyzing the release of copeptin from the heart in acute myocardial infarction using a transcoronary gradient model. Sci Rep 2016; 6: 20812.
117. Jougasaki M, Burnett JC, Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000; 66: 855-872.
118. Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51: 1823-1829.
119. Klip IT, Voors AA, Anker SD, et al. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart 2011; 97: 892-898.
120. Bahrmann P, Christ M, Hofner B, et al. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department. Eur Heart J Acute Cardiovasc Care 2016; 5: 568-578.
121. Gottsater M, Ford LB, Ostling G, et al. Adrenomedullin is a marker of carotid plaques and intima-media thickness as well as brachial pulse pressure. J Hypertens 2013; 31: 1959-1965.
122. Neumann JT, Tzikas S, Funke-Kaiser A, et al. Association of mr-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis 2013; 228: 451-459.
123. Haaf P, Twerenbold R, Reichlin T, et al. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients. Int J Cardiol 2013; 168: 1048-1055.
124. Cea LB. Natriuretic peptide family: new aspects. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 87-98.
125. Mueller T, Gegenhuber A, Dieplinger B, et al. Long-term stability of endogenous b-type natriuretic peptide (BNP) and amino terminal probnp (NT-PROBNP) in frozen plasma samples. Clin Chem Lab Med 2004; 42: 942-944.
126. Ndumele CE, Matsushita K, Sang Y, et al. N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2016; 133: 631-638.
127. Daniels LB, Clopton P, deFilippi CR, et al. Serial measurement of n-terminal pro-b-type natriuretic peptide and cardiac troponin t for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2015; 170: 1170-1183.
128. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
129. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogeneity has a major impact on the measurement of circulating n-terminal fragments of a- and b-type natriuretic peptides. Clin Chem 2004; 50: 1576-1588.
130. Shah RV, Truong QA, Gaggin HK, et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012; 33: 2197-2205.
131. Karakas M, Jaensch A, Breitling LP, et al. Prognostic value of midregional pro-a-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years. Clin Chem 2014; 60: 1441-1449.
132. McMurray JJ, Adamopoulos S, Anker SD, et al. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the esc. Eur Heart J 2012; 33: 1787-1847.
133. Januzzi JL, Jr. St2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res 2013; 6: 493-500.
134. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin- 1-like cytokine that signals via the IL-1 receptor- related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
135. Dhillon OS, Narayan HK, Khan SQ, et al. Pre-discharge risk stratification in unselected stemi: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol 2013; 167: 2182-2188.
136. Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One 2014; 9: e95055.
137. Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011; 107: 259-267.
138. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011; 4: 180-187.
139. Dieplinger B, Egger M, Haltmayer M, et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the ludwigshafen risk and cardiovascular health study. Clin Chem. 2014; 60: 530-540.
140. Chen LQ, de Lemos JA, Das SR, et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population- based cohort: the Dallas heart study. Clin Chem 2013; 59: 536-546.
141. Kohli P, Bonaca MP, Kakkar R, et al. Role of ST2 in non-st-elevation acute coronary syndrome in the merlin-timi 36 trial. Clin Chem 2012; 58: 257-266.
142. Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol 2014; 10: 525-539.
143. O'Malley RG, Bonaca MP, Scirica BM, et al. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the merlin-timi 36 trial (metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36). J Am Coll Cardiol 2014; 63: 1644-1653.
144. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble st2, high-sensitivity troponin t- and n-terminal pro-b-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13: 718-725.
145. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013; 168: 2186-2194.
146. Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for longterm heart failure risk stratification: St2 versus galectin-3. J Am Coll Cardiol 2014; 63: 158-166.
147. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev 2016; 68: 357-418.
148. Perez AL, Grodin JL, Wu Y, et al. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ascend- hf biomarker substudy. Eur J Heart Fail 2016; 18: 290-297.
149. Khan SQ, Dhillon O, Struck J, et al. C-terminal pro-endothelin- 1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial infarction Peptide (LAMP) study. Am Heart J 2007; 154: 736-742.
150. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012; 125: 233-240.
151. MacKinnon AC, Liu X, Hadoke PW, et al. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013; 23: 654-663.
152. Maiolino G, Rossitto G, Pedon L, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015; 35: 725-732.
153. Lisowska A, Knapp M, Tycinska A, et al. Predictive value of galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid imt values in these patients: a mid-term prospective cohort study. Atherosclerosis 2016; 246: 309-317.
154. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616-635.
155. van Kimmenade RR, Januzzi JL, Jr., Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-1224.
156. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the deal-hf study. Clin Res Cardiol 2010; 99: 323-328.
157. Yin QS, Shi B, Dong L, et al. Comparative study of galectin- 3 and b-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol 2014; 11: 79-82.
158. Chen YS, Gi WT, Liao TY, et al. Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis. Biomark Med 2016; 10: 329-342.
159. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbb2 in neural and cardiac development. Nature 1995; 378: 394-398.
160. Kuramochi Y, Cote GM, Guo X, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbb4 signaling. J Biol Chem 2004; 279: 51141-51147.
161. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/erbb signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007; 116: 954-960.
162. Geisberg CA, Wang G, Safa RN, et al. Circulating neuregulin- 1beta levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis 2011; 22: 577-582.
163. Barwari T, Joshi A, Mayr M. Micrornas in cardiovascular disease. J Am Coll Cardiol 2016; 68: 2577-2584.
164. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microrna: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-666.
165. Karakas M, Schulte C, Appelbaum S, et al. Circulating micrornas strongly predict cardiovascular death in patients with coronary artery disease-results from the large atherogene study. Eur Heart J 2016; pii: ehw250.
166. Bye A, Rosjo H, Nauman J, et al. Circulating micrornas predict future fatal myocardial infarction in healthy individuals- the HUNT study. J Mol Cell Cardiol 2016; 97: 162-168.
167. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating micrornas and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290-299.